Form 4: Phillip Frost and Frost Gamma Investments Trust Report OPKO Health Stock and Convertible Note Transactions

Phillip Frost, along with Frost Gamma Investments Trust, reports acquiring OPKO Health common stock and convertible notes, reflecting changes in beneficial ownership.

Summary

• Phillip Frost, CEO and Chairman of OPKO Health, along with Frost Gamma Investments Trust, filed a Form 4 detailing changes in beneficial ownership.
• On February 28, 2025, Frost purchased 67,434 shares of OPKO Health common stock at $1.71 per share.
• Frost also acquired $1,000,000 worth of 3.75% Convertible Notes due 2029 at a price of $1.15.
• The convertible notes, issued on January 9, 2024, are convertible into common stock at a price of $1.15 after September 15, 2028, and before January 15, 2029.
• Frost's indirect ownership includes 213,301,448 shares held by Frost Gamma Investments Trust and 30,127,177 shares held by Frost Nevada Investments Trust.
• Frost disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the disclaimer of beneficial ownership tempers the enthusiasm.

Positives

• The purchase of shares and convertible notes by a key insider like Phillip Frost could be interpreted as a positive signal about the company's prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the conversion terms of the notes provide a potential future dilution scenario.

Management Comments

• Phillip Frost disclaims beneficial ownership of the indirectly held securities except to the extent of any pecuniary interest.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's view of the company's prospects. The purchase of shares and convertible notes by Phillip Frost could be seen as a positive sign.

Comparison to Industry Standards

• Comparing OPKO's convertible note terms to similar biotech companies, the 3.75% interest rate is within the typical range for such instruments.
• The conversion price of $1.15 will be compared to the market price of OPKO's shares as the conversion date approaches to determine the potential impact on shareholders.

Stakeholder Impact

• The transactions could positively influence shareholder sentiment.
• The potential conversion of notes could dilute existing shareholders in the future.

Key Dates